Cover Image

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Jennifer Carew, Francis GilesInstitute for Drug Development, Cancer Therapy and Research Centre, University of Texas Health Science Centre at San Antonio, USAAbstract: Chronic myeloid leukemia (CML) is the consequence of a single balanced...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ronan Swords (Author), Devalingam Mahalingam (Author), Swaminathan Padmanabhan (Author), Jennifer Carew (Author), Francis Giles (Author)
Format:	Book
Published:	Dove Medical Press, 2009-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Imatinib- and Nilotinib-Induced Lichenoid Eruption in Chronic Myeloid Leukemia: A Rare Case Report
by: Meenakshi Sachdeva, et al.
Published: (2023)

The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
by: Muhammad Darwin Prenggono, et al.
Published: (2021)

Development and targeted use of nilotinib in chronic myeloid leukemia
by: Carmen Fava, et al.
Published: (2008)

Nilotinib Induced Keratosis Pilaris in a Female With Chronic Myeloid Leukemia
by: Ranjana Beniwal, et al.
Published: (2024)

Nilotinib and Imatinib Utilization in Iran over 14 years
by: Ava Mansouri, et al.
Published: (2020)

Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
by: N. A. Avxentyev, et al.
Published: (2018)

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
by: Hyacinthe Johnson-Ansah, et al.
Published: (2022)

Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
by: Aypara Hasanova, et al.
Published: (2023)

Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib
by: Pantazi D, et al.
Published: (2019)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

Imatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia
by: Pradeep Balasubramanian, et al.
Published: (2015)

Imatinib associated discoid lupus erythematosus in a patient with chronic myeloid leukemia
by: Priya Sarlashkar, BS, et al.
Published: (2024)

Nilotinib-Induced Elephantine Psoriasis In a Patient With Chronic Myeloid Leukemia: A Rare Case Report and Literature Review
by: Seyedeh Fatemeh Sadatmadani, et al.
Published: (2022)

Multiple eruptive dermatofibromas secondary to imatinib mesylate in a patient with chronic myeloid leukemia
by: Francisco J Lira-Valero, et al.
Published: (2021)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
by: Martin Henkes, et al.
Published: (2008)

Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients
by: Heriberto Bruzzoni-Giovanelli, et al.
Published: (2024)

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents
by: Hari Krishna Ananthula, et al.
Published: (2018)

Polymorphisms in Drug Transporter and Metabolism Genes Associated with Resistance to Imatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
by: Ana Marcela Arrieta Gómez, et al.
Published: (2023)

A validated UPLCâMS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma
by: Jing Zeng, et al.
Published: (2017)

Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience
by: Josephine A. Adattini, et al.
Published: (2022)

Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
by: Parveen Jain, et al.
Published: (2013)

Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia
by: Qing Wang, et al.
Published: (2020)

Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events
by: Pavel Burda, et al.
Published: (2024)

The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia
by: Camillo Porta, et al.
Published: (2011)

Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia
by: Yan Chen, et al.
Published: (2020)

Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia
by: Josephine A. Adattini, et al.
Published: (2023)

Study of correlation between imatinib mesylate plasma levels and hematological profile of patients undergoing treatment for chronic myeloid leukemia
by: Emanuelle S. Dal Ponte, et al.
Published: (2017)

Profile of imatinib in pediatric leukemia
by: Burke MJ
Published: (2014)

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
by: Caroline Regina de Jesus, et al.
Published: (2011)

PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration
by: Rui Su, et al.
Published: (2023)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
by: Jae Wook Lee, et al.
Published: (2011)

Treatment free remission in pediatric chronic myeloid leukemia
by: Meena Satishkumar, et al.
Published: (2023)

Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo
by: Bharathi M. Rajamani, et al.
Published: (2023)

Long-term imatinib therapy adversely affects bone health in children with chronic myeloid leukemia: A prospective, cross-sectional, descriptive study
by: Srinivasan PP, et al.
Published: (2024)

Nilotinib-Induced Keratosis Pilaris
by: Wai Mun Sean Leong, et al.
Published: (2016)

Betulinic Acid-Brosimine B Hybrid Compound Has a Synergistic Effect with Imatinib in Chronic Myeloid Leukemia Cell Line, Modulating Apoptosis and Autophagy
by: Julia Biz Willig, et al.
Published: (2023)

Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
by: Gian Paolo Bombeccari, et al.
Published: (2017)

Cutaneous myeloid sarcoma associated with chronic myeloid leukemia
by: Erica Rodrigues de Araujo Vasconcelos, et al.
Published: (2017)

Pediatric chronic myeloid leukemia in myeloid blast crisis
by: Biswajit Dey, et al.
Published: (2023)

Isolated Ocular Manifestation of Relapsed Chronic Myelogenous Leukemia Presenting as Myeloid Blast Crisis in a Patient on Imatinib Therapy: A Case Report and Review of the Literature
by: Rohit Gulati, et al.
Published: (2015)